Brief Title
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
Official Title
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors
Brief Summary
For patients with severe aplastic anemia (SAA) who have failed to respond to
immunosuppressive therapy and lack an HLA identical family member, our objectives are to make
an initial assessment of the safety and efficacy of allogenic stem cell transplantation from
either a matched unrelated donor or a mismatched reacted donor using the conditioning regimen
of Cytoxan, reduced total body irradiation (TBI) and Campath IH. The principle measures of
safety and efficacy will be :
1. Patient survival probability at 100 days, 1 year and 2 years.
2. Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and
chronic GVHD within 6 months and 2 years.
3. Engraftment at 6 months, 1 year and 2 years
Detailed Description
The objective of this trial is to make an initial assessment for this new treatment regimen
and to show it is equal or superior to the current standard practice. With this initial
assessment be hope to gain information suggesting further study of this regimen or
discontinuation of this regimen before exposing large numbers of patients to this new
treatment option. We also will gain experience with this new regimen giving insights as to
possible modifications in dosing and monitoring and selection of patients for future
treatment in case of positive results. For this initial study we plan to enroll up to 24
patients.
Study Phase
Phase 1
Study Type
Interventional
Primary Outcome
1. Engraftment at 6 months, 1 year and 2 years 2.Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years
Secondary Outcome
Patient survival probability at 100 days, 1 year and 2 years.
Condition
Anemia, Aplastic
Intervention
Cyclophosphamide,Campath IH and TBI
Study Arms / Comparison Groups
No Arms
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
8
Start Date
February 2007
Completion Date
August 16, 2016
Primary Completion Date
August 16, 2016
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of SAA based on bone marrow aspirate and biopsy results. Failure to respond
to immunosuppressive therapy and/or lack of an HLA identical family member.
- A 10/10 or 9/10 HLA matched unrelated donor or a 9/10 matched related donor available
after high resolution typing.
Exclusion Criteria:
- Patients with Aplastic anemia and active infection must be treated to maximally
resolve this problem before beginning the conditioning regimen.
- HIV seropositive patients
- Patients who have clonal cytogenetic abnormalities or a myelodysplastic syndrome.
- Patient greater than 60 years of age.
- Women who are pregnant or nursing.
- Patients with active hepatitis
- Patients with severe cardiac dysfunction defined as shortening fraction <25%.
- Patients with severe renal dysfunction defined as creatinine clearance
<40ml/mim/1.73m2.
- Patient with severe pulmonary dysfunction with FEV1, FVC and DLCO 40% of predicted or
3 SD below normal.
Gender
All
Ages
N/A - 60 Years
Accepts Healthy Volunteers
No
Contacts
Shakila P. Khan, M.D., ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT00578266
Organization ID
06-006216
Responsible Party
Principal Investigator
Study Sponsor
Mayo Clinic
Study Sponsor
Shakila P. Khan, M.D., Principal Investigator, Mayo Clinic
Verification Date
March 2017